Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.5.1.52 (
PNGase F
)
1,527
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The human
promyelocytic leukemia
ell line, HL-60, synthesized a class of high-molecular-weight (M.W. 5000 to 7000), N-linked glycopeptides as the major class of protein-bound carbohydrates. Small glycopeptides (M.W. 2500 to 3500), typical of most mammalian cells except erythrocytes, represented a minor component in these cells. The large glycopeptides were labeled efficiently with fucose, glucosamine, and galactose but only poorly with mannose. They were found not to be glycolipids, glycosaminoglycans, or mucin-type glycopeptides and were not susceptible to exoglycosidases, but they were partially degraded by endo-beta-galactosidases. These characteristics are similar to those of the large glycopeptides synthesized by erythrocytes, by another human myeloid leukemia cell line (K562), and by human and murine teratocarcinoma cells. High-molecular-weight glycopeptides predominated on another human myeloid leukemia cell line KG1, but they were expressed at low levels on both a human monocytic leukemia cel line (THP-1) and a human T-lymphoblastoid cell line (Jurkat). When HL-60 cells were induced to differentiate into macrophage-like cells with phorbol esters, the proportion of large glycopeptides decreased, and the production of small glycopeptides predominated. This shift was observed within the first several hr after exposure to phorbol esters and was temporally related to the acquisition of adherent properties by the induced cells. In contrast, when HL-60 cells were induced to differentiate into granulocytes by dimethyl sulfoxide, hypoxanthine, or retinoic acid, they continued to synthesize glycopeptides similar to uninduced cells. Human peripheral blood granulocytes synthesized primarily large glycopeptides, whereas monocytes and lymphocytes synthesized mostly small glycopeptides. These results indicate that the synthesis of high-molecular-weight glycopeptides is a property of human myeloid leukemia cell lines and that it persists throughout myeloid differentiation. A proportionate decrease in the synthesis of these large
glycopeptidase
is a part of the differentiation program for monocytes and macrophages.
...
PMID:Decreased synthesis of high-molecular-weight glycopeptides in human promyelocytic leukemic cells (HL-60) during phorbol ester-induced macrophage differentiation. 694 6
We evaluated two independent models of eosinophil differentiation for their ability to synthesize the ribonuclease toxins eosinophil-derived neurotoxin (EDN) and eosinophil cationic protein (ECP). Cells from the clone 15 subline of HL-60 (human
promyelocytic leukemia
) produced both EDN and ECP; production of EDN increased in response to butyric acid (BA). CD34+ peripheral blood progenitor cells (PBPCs) grown with cytokines promoting eosinophil differentiation also produced EDN. EDN from both the clone 15 and PBPCs was more heterogeneous and heavily glycosylated (approximately 22-45 kDa) than EDN from the mature peripheral blood eosinophils (18-25 kDa). The heterogeneity of EDN from the clone 15 cells was not altered by endoglycosidase Hf, whereas treatment with peptide-N-glycosidase F (
PNGase F
) produced a single-band immunoreactive band (approximately 15 kDa). In contrast, only the highest molecular weight forms of EDN from differentiated PBPCs were eliminated by PNTGase F (reduced to 22-35 kDa), suggesting the presence of uncharacteristic forms of posttranslational modification. Synthesis of hyperglycosylated proteins has not been previously reported in PBPCs and is a feature shared with tumor cells and cell lines.
...
PMID:Hyperglycosylation of eosinophil ribonucleases in a promyelocytic leukemia cell line and in differentiated peripheral blood progenitor cells. 761 5